16:00
Opening & introduction
Dr Jean-Yves ORTHOLAND
EDELRIS, Lyon, France
Dr Allen ANNIS
AILERON THERAPEUTICS, Cambridge, United States
16:10
Targeting RNA With Small Molecules Using Affinity-Selection Mass Spectrometry (KL01)
Dr Elliott B. NICKBARG
MERCK & CO., INC., Boston, United States
Elliott Nickbarg received his undergraduate degree from the University of Chicago and a doctorate in Chemistry from Harvard University. After completing a postdoctoral appointment at the University of Pennsylvania, he joined Genetics Institute, Inc. of Cambridge MA (later part of Wyeth Pharmaceuticals) and worked on applications of proteomics technology. He then joined Neogenesis Pharmaceuticals (later part of Schering-Plough) and helped to develop applications for the ALIS screening system, and has continued to apply ALIS and related technologies as part of the Quantitative Biosciences department at Merck Research Laboratories in Boston MA. He has approximately 25+ years of experience doing drug discovery in Biotechnology and Pharmaceutical companies.
16:55
Discovery of Bioactive Natural Products Using Affinity Selection-Mass Spectrometry (PL01)
Prof. Richard VAN BREEMEN
OREGON STATE UNIVERSITY, Corvallis, United States
Richard B. van Breemen is Professor of Pharmaceutical Sciences in the College of Pharmacy, the Global Hemp Innovation Center, and the Linus Pauling Institute at Oregon State University. He received his B.A. in Chemistry from Oberlin College and Ph.D. in Pharmacology and Experimental Therapeutics from the Johns Hopkins University. After post-doctoral research at Johns Hopkins University, he taught chemistry at North Carolina State University and medicinal chemistry and pharmacognosy at the University of Illinois College of Pharmacy before joining Oregon State University in 2018. His research concerns the discovery of pharmacologically active natural products using affinity selection-mass spectrometry, and the safety and efficacy of botanical dietary supplements.
17:30
Short break
17:40
Accelerating Drug Discovery with the Integration of Affinity Selection Mass Spectrometry (PL02)
Dr Damian HOUDE
RELAY THERAPEUTICS, Cambridge, United States
Damian Houde, PhD. is a Principal Scientist within the Early Research department at Relay Therapeutics. Prior to that Damian was the Director of Process Analytics at Codiak BioSciences in Cambridge, MA (2016-2018). He also worked as a scientist at Biogen in Cambridge, MA for 14 years (2002-2016). His technical areas of expertise are concentrated in the separation and physical sciences associated with the characterization of biopolymers. Much of his work has centered on assessing the physicochemical properties, microheterogeneity, and aggregation propensity of proteins using mass spectrometry, chromatography, light scattering, and various forms of spectroscopy. His responsibilities have focused on providing biophysical information on the higher-order structure and structural dynamics of proteins and the development and evaluation of analytical tools such as HDX-MS to support this. Damian attended Northeastern University where he received a BS in Biology in 1998, a Graduate Certificate in Bioinformatics in 2004, and a PhD in Chemistry in 2010.
18:15
Fishing from an Exclusive Pond Using AS-MS (PL03)
Dr Didier ROCHE
EDELRIS, Lyon, France
Didier Roche, Ph.D., is Chief Scientific Officer at Edelris, a company he has co-founded in 2005. Edelris has pioneered the design and synthesis of Natural Product inspired libraries and is now developing a high throughput AS-MS screening platform for hit generation. Didier received his Ph.D. from the University of Strasbourg and joined for a post-doctoral position Novartis where he pursed his carrier as process-chemist. He moved back to medicinal chemistry after joining Merck KGaA where he led a group of 25 chemists for the diabetes division and contributed to the clinical development of 3 drug candidates. Didier has a broad interest for the development of new technologies in drug discovery.
18:30
Closing remarks Day 1